StockData
Adagio Medical Holdings, Inc. logo

Adagio Medical Holdings, Inc. (ADGM) stock

ADGMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 2/30
$1.65+0.04 (+2.48%)

Close on Nov 17, 2026Market cap $1.37MP/E –Yield –

Adagio Medical r&d expenses

Research and development expenses are spending on new products and technology.

Adagio Medical's R&D Expenses for the twelve months ending Sep 30, 2026 was $9.23M. For fiscal 2025 it was $10.64M, down 30.9% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.64M-30.9%
FY2023Dec 31, 2023$15.40M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.80M-35.1%
Q2 FY2026Jun 30, 2026$2.45M+24.3%
Q1 FY2026Mar 31, 2026$2.74M-25.1%
Q4 FY2025Dec 31, 2025$2.24M-22.0%
Q3 FY2025Sep 30, 2025$2.77M-20.0%
Q2 FY2025Jun 30, 2025$1.97M+11.1%
Q1 FY2025Mar 31, 2025$3.66M-17.2%
Q2 FY2024Jun 30, 2024$2.87M–
Q1 FY2024Mar 31, 2024$3.47M–
Q4 FY2023Dec 31, 2023$1.77M–
Q3 FY2023Sep 30, 2023$4.42M–

More Adagio Medical figures

See a number that looks wrong?